|
 The Galleri test looks at the DNA in a patient's blood to determine
if any come from cancer cells. Earlier diagnosis of cancers leads to
dramatically increased survival rates.
The NHS said it wanted to recruit 140,000 volunteers in England to
see how well the test worked as part of a randomised control trial.
Half of the participants will have their blood sample screened with
the Galleri test right away.
"We need to study the Galleri test carefully to find out whether it
can significantly reduce the number of cancers diagnosed at a late
stage," said Peter Sasieni, professor of cancer prevention at King's
College London.
"The test could be a game changer for early cancer detection and we
are excited to be leading this important research."
[to top of second column] |
 Lung cancer is by far the most
common cause of cancer death in the United
Kingdom, accounting for around a fifth of all
cancer deaths. Lung, bowel, prostate and breast
cancers account for 45% of the United Kingdom's
cancer deaths, the NHS said.
U.S. life sciences company Illumina Inc said
last month it had completed its $7.1 billion
acquisition of Grail. Illumina said it will
operate Grail separately from its existing
business.
(Reporting by Guy Faulconbridge; Editing by Mike
Harrison)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
